Elutia (ELUT) vs Quince Therapeutics (QNCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Elutia (ELUT) has outperformed Quince Therapeutics (QNCX) over the past year, losing 6.9% versus a loss of 92.4%. Over five years, ELUT leads with a -84.8% price change compared with -99.8% for QNCX. Elutia is the larger company by market cap ($36.6 million vs $29.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELUT | QNCX |
|---|---|---|
| Share price | $0.8273 | $29.36 |
| Market cap | $36.64M | $29.86M |
| 1-day change | +0.88% | +9.88% |
| YTD return | +19.38% | -95.62% |
| 1-year return | -6.94% | -92.35% |
| 5-year return | -84.82% | -99.77% |
| EPS (TTM) | $-0.64 | $-214.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.39 | $910.00 |
| 52-week low | $0.50 | $15.10 |
| Distance from 52-week high | -40.27% | -96.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +504.38% | +156.91% |
| Average volume | 185.82K | 28.83K |
| Shares outstanding | 44.29M | 1.02M |
| Employees | 25 | 38 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELUT has outperformed QNCX by 85.4 percentage points over the past year.
About Elutia
ELUT stock →Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.
Healthcare · Medical Devices · 25 employees
About Quince Therapeutics
QNCX stock →Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Healthcare · Biotechnology · 38 employees
ELUT vs QNCX FAQ
Which is bigger, Elutia or Quince Therapeutics?
Elutia (ELUT) is larger, with a market capitalization of $36.64M compared with $29.86M for Quince Therapeutics (QNCX).
Which stock has performed better over the past year, ELUT or QNCX?
ELUT returned -6.94% over the past 12 months, compared with -92.35% for QNCX (price return, excluding dividends). Past performance does not predict future results.
Are Elutia and Quince Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Medical Devices for Elutia and Biotechnology for Quince Therapeutics.